Fudan University: Nasopharyngeal Carcinoma trials

The registry lists 27 Nasopharyngeal Carcinoma studies with Fudan University as lead sponsor. 13 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 2 16Phase 3 6No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Induction Chemotherapy Response-Guided Reduced-Dose Radiotherapy for Nasopharyngeal CarcinomaNot yet recruitingNCT07789158Phase 2
• Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal CarcinomaRecruitingNCT07762976Phase 2
• Individualized Neck Cervical Irradiation Prophylaxis Trial of NPCRecruitingNCT07303023Phase 3
• Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After RadiotherapyRecruitingNCT07067268Phase 2
• Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPCRecruitingNCT06177301Phase 3
• PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction ChemotherapyRecruitingNCT06156878Phase 2
• Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant ChemotherapyRecruitingNCT05772208Phase 3
• Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver MetastasesRecruitingNCT05771025Not applicable
• Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant ChemotherpyRecruitingNCT05674305Phase 3
• Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICTRecruitingNCT05628922Phase 2
• Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal CarcinomaRecruitingNCT05587543Early Phase 1
• Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line ChemotherapyRecruitingNCT04978012Phase 2
• SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT04351282Not applicable
• Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT04921995Phase 2
• Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04517214Phase 2
• Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction ChemotherapyCompletedNCT04508816Phase 2
• S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaCompletedNCT03668366Phase 2
• Radiation-associated Carotid Artery Disease in Patients With Nasopharyngeal CarcinomaStatus unknownNCT03568032
• Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 StageStatus unknownNCT03403829Phase 3
• Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPCCompletedNCT02012062Phase 3
• Treatment of Cerebral Radiation Necrosis With GM1, a Prospective StudyStatus unknownNCT01884987
• Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal CancerStatus unknownNCT01614938Phase 2
• SOX as Salvage Treatment in Nasopharyngeal CarcinomaTerminatedNCT01403259Phase 2
• Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma (NPC)Status unknownNCT00817583Phase 2
• Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal CarcinomaStatus unknownNCT00817258Phase 2
• Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage Ⅲ Nasopharyngeal CarcinomaStatus unknownNCT00816855Phase 2
• Phase Ⅱ Study of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Stage ⅣAB Nasopharyngeal CarcinomaStatus unknownNCT00816816Phase 2